Patents by Inventor Gilles Chambournier
Gilles Chambournier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10550087Abstract: Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.Type: GrantFiled: November 17, 2015Date of Patent: February 4, 2020Assignee: Aerie Pharmaceuticals, Inc.Inventors: Jill Marie Sturdivant, Mitchell A. deLong, Gilles Chambournier, Michael G. Pamment, Victor Fedij
-
Publication number: 20200002261Abstract: The present invention provides processes for preparing a prostacyclin analogue of Formula I or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.Type: ApplicationFiled: September 11, 2019Publication date: January 2, 2020Applicant: CAYMAN CHEMICAL COMPANY INCORPORATEDInventors: Kirk William Hering, Gilles CHAMBOURNIER, Gregory William ENDRES, Victor FEDIJ, Thomas James KRELL, II, Hussien Mahmoud MAHMOUD
-
Patent number: 10450257Abstract: The present invention provides processes for preparing a prostacyclin analog of Formula I or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.Type: GrantFiled: January 18, 2018Date of Patent: October 22, 2019Assignee: Cayman Chemical Company IncorporatedInventors: Kirk William Hering, Gilles Chambournier, Gregory William Endres, Victor Fedij, Thomas James Krell, II, Hussein Mahmoud Mahmoud
-
Publication number: 20180370919Abstract: Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.Type: ApplicationFiled: November 17, 2015Publication date: December 27, 2018Inventors: Jill Marie Sturdivant, Mitchell A. deLong, Gilles Chambournier, Michael G. Pamment, Victor Fedij
-
Patent number: 10155716Abstract: The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.Type: GrantFiled: December 22, 2017Date of Patent: December 18, 2018Assignee: Cayman Chemical Company IncorporatedInventors: Gilles Chambournier, Gregory William Endres, Kirk William Hering, Victor Fedij, Hussein Mahmoud Mahmoud
-
Publication number: 20180141889Abstract: The present invention provides processes for preparing a prostacyclin analogue of Formula I or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.Type: ApplicationFiled: January 18, 2018Publication date: May 24, 2018Applicant: CAYMAN CHEMICAL COMPANY INCORPORATEDInventors: Kirk William Hering, Gilles Chambournier, Gregory William Endres, Victor Fedij, Thomas James Krell, II, Hussein Mahmoud Mahmoud
-
Publication number: 20180118656Abstract: The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.Type: ApplicationFiled: December 22, 2017Publication date: May 3, 2018Applicant: Cayman Chemical Company IncorporatedInventors: Gilles Chambournier, Gregory William Endres, Kirk William Hering, Victor Fedij, Hussein Mahmoud Mahmoud
-
Patent number: 9908834Abstract: The present invention provides processes for preparing a prostacyclin analog of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.Type: GrantFiled: May 1, 2017Date of Patent: March 6, 2018Assignee: Cayman Chemical Company IncorporatedInventors: Kirk William Hering, Gilles Chambournier, Gregory William Endres, Victor Fedij, Thomas James Krell, II, Hussein Mahmoud Mahmoud
-
Patent number: 9890104Abstract: The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.Type: GrantFiled: November 7, 2014Date of Patent: February 13, 2018Assignee: Cayman Chemical Company IncorporatedInventors: Gilles Chambournier, Gregory William Endres, Kirk William Hering, Victor Fedij, Hussein Mahmoud Mahmoud
-
Patent number: 9840468Abstract: Described are methods for the preparation of 6-aminoisoquinoline, a useful intermediate compound in the synthesis of kinase inhibitors.Type: GrantFiled: December 30, 2016Date of Patent: December 12, 2017Assignee: Aerie Pharmaceuticals, Inc.Inventors: Gilles Chambournier, Mitchell A. deLong
-
Publication number: 20170297995Abstract: The present invention provides processes for preparing a prostacyclin analogue of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.Type: ApplicationFiled: May 1, 2017Publication date: October 19, 2017Applicant: CAYMAM CHEMICAL COMPANY INCORPORATEDInventors: Kirk William Hering, Gilles Chambournier, Gregory William Endres, Victor Fedij, Thomas James Krell, II, Hussein Mahmoud Mahmoud
-
Publication number: 20170137384Abstract: Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.Type: ApplicationFiled: November 17, 2015Publication date: May 18, 2017Inventors: Jill M. Sturdivant, Mitchell A. deLong, Gilles Chambournier, Michael G. Pamment, Victor Fedij
-
Patent number: 9643927Abstract: Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.Type: GrantFiled: November 17, 2015Date of Patent: May 9, 2017Assignee: Aerie Pharmaceuticals, Inc.Inventors: Jill M. Sturdivant, Mitchell A. deLong, Gilles Chambournier, Michael G. Pamment, Victor Fedij
-
Publication number: 20160289158Abstract: The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.Type: ApplicationFiled: November 7, 2014Publication date: October 6, 2016Applicant: CAYMAN CHEMICAL COMPANY INCORPORATEDInventors: GILLES CHAMBOURNIER, GREGORY WILLIAM ENDRES, KIRK WILLIAM HERING, VICTOR FEDIJ, HUSSEIN MAHMOUD MAHMOUD
-
Publication number: 20150315114Abstract: The present invention provides processes for preparing a prostacyclin analogue of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.Type: ApplicationFiled: December 6, 2013Publication date: November 5, 2015Inventors: Kirk Willam HERING, Gilles CHAMBOURNIER, Gregory William ENDRES, Victor FEDIJ, Thomas James KRELL, II, Hussein Mahmoud MAHMOUD
-
Patent number: 8901319Abstract: A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.Type: GrantFiled: October 16, 2009Date of Patent: December 2, 2014Assignee: Cayman Chemical Company, IncorporatedInventors: Gilles Chambournier, Andriy Kornilov, Hussein M. Mahmoud, Ivan Vesely, Stephen D. Barrett
-
Patent number: 8487116Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.Type: GrantFiled: November 9, 2011Date of Patent: July 16, 2013Assignee: AbbVie Inc.Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Chih-Hung Lee, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink
-
Publication number: 20120283451Abstract: A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.Type: ApplicationFiled: October 16, 2009Publication date: November 8, 2012Inventors: Gilles Chambournier, Andriy Kornilov, Hussein M. Mahmoud, Ivan Vesely, Stephen D. Barrett
-
Patent number: 8071762Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.Type: GrantFiled: April 30, 2008Date of Patent: December 6, 2011Assignee: Abbott LaboratoriesInventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Marvin R. Leanna, Russell D. Cink
-
Publication number: 20080287676Abstract: The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2 and Ar1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.Type: ApplicationFiled: April 30, 2008Publication date: November 20, 2008Applicant: Abbott LaboratoriesInventors: Arthur R. Gomtsyan, Erol K. Bayburt, Chih-Hung Lee, John R. Koenig, Robert G. Schmidt, Kirill A. Lukin, Gilles Chambournier, Margaret Chi-Ping Hsu, Robert M. Leanna, Russell D. Cink